| Title |
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2012
|
| DOI | 10.1007/s00262-012-1263-z |
| Pubmed ID | |
| Authors |
Erik H. J. G. Aarntzen, I. Jolanda M. de Vries, Joop H. Göertz, Marjo Beldhuis-Valkis, Huberdina M. L. M. Brouwers, Mandy W. M. M. van de Rakt, Renate G. van der Molen, Cornelis J. A. Punt, Gosse J. Adema, Paul J. Tacken, Irma Joosten, Joannes F. M. Jacobs |
| Abstract |
Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it has not been possible to monitor the dynamics of KLH-specific antibody (Ab) responses after in vivo KLH exposure. We designed a quantitative assay to measure KLH-specific Abs in humans and retrospectively studied the relation between vaccination parameters and the vaccine-induced anti-KLH Ab responses. |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 19% |
| Student > Bachelor | 7 | 15% |
| Student > Master | 6 | 13% |
| Student > Ph. D. Student | 4 | 9% |
| Other | 4 | 9% |
| Other | 8 | 17% |
| Unknown | 9 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 11 | 23% |
| Medicine and Dentistry | 8 | 17% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Immunology and Microbiology | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 9 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2012.
All research outputs
#7,454,298
of 22,789,076 outputs
Outputs from Cancer Immunology, Immunotherapy
#1,037
of 2,881 outputs
Outputs of similar age
#53,761
of 162,775 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#11
of 31 outputs
Altmetric has tracked 22,789,076 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 162,775 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.